Asthma Therapeutics in Major Developed Markets Growth & Trend to 2020 Radiant Insights, Inc
Summary Radiant Insights, a leading business intelligence provider, has released its latest research report,"Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations".The asthma therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4%. This is in spite of generic erosion facing several of the leading asthma brands, such as Advair (fluticasone propionate/salmeterol xinafoate), Symbicort (budesonide/formoterol fumarate) and Xolair (omalizumab), and is a consequence of new market entrants and rising disease prevalence. The global prevalence of asthma is significant, believed to affect approximately 300 million people worldwide. This burden is predicted to increase in future, reaching 400 million by 2025. Access This Full Report @ http://www.radiantinsights.com/research/asthma-therapeutics-in-major-developed-markets-to-2020-personalized-treatment-for-severe-asthma-to-drive-market-growth-despite-patent-expirations Although the majority of asthma patients are able to manage their symptoms effectively using currently marketed products, some remain inadequately controlled with these same products. This unmet need, coupled with rising global prevalence, has resulted in strong industry interest. Consequently, the current asthma pipeline is highly innovative, featuring several promising molecules in late-stage drug development. Biologics and monoclonal antibodies, the latter in particular, are gaining prominence within the indication. Novel monoclonal antibodies such as mepolizumab, reslizumab, lebrikizumab, and dupilumab target Interleukins (IL), or IL receptors, and have demonstrated potential in severe and inadequately controlled eosinophilic asthma, in turn representing a shift towards personalized therapy. Despite the fact that they target only a small patient sub-set, they are likely to be priced highly and to drive market growth, offsetting the impact of generic erosion.
Summary
Radiant Insights, a leading business intelligence provider, has released its latest research report,"Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations".The asthma therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4%. This is in spite of generic erosion facing several of the leading asthma brands, such as Advair (fluticasone propionate/salmeterol xinafoate), Symbicort (budesonide/formoterol fumarate) and Xolair (omalizumab), and is a consequence of new market entrants and rising disease prevalence.
The global prevalence of asthma is significant, believed to affect approximately 300 million people worldwide. This burden is predicted to increase in future, reaching 400 million by 2025.
Access This Full Report @ http://www.radiantinsights.com/research/asthma-therapeutics-in-major-developed-markets-to-2020-personalized-treatment-for-severe-asthma-to-drive-market-growth-despite-patent-expirations
Although the majority of asthma patients are able to manage their symptoms effectively using currently marketed products, some remain inadequately controlled with these same products. This unmet need, coupled with rising global prevalence, has resulted in strong industry interest.
Consequently, the current asthma pipeline is highly innovative, featuring several promising molecules in late-stage drug development. Biologics and monoclonal antibodies, the latter in particular, are gaining prominence within the indication. Novel monoclonal antibodies such as mepolizumab, reslizumab, lebrikizumab, and dupilumab target Interleukins (IL), or IL receptors, and have demonstrated potential in severe and inadequately controlled eosinophilic asthma, in turn representing a shift towards personalized therapy. Despite the fact that they target only a small patient sub-set, they are likely to be priced highly and to drive market growth, offsetting the impact of generic erosion.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
- Comprehensive analysis of the asthma pipel<strong>in</strong>e by phase of development, molecule type, and molecular<br />
target and novelty, and comparative analysis of the most promis<strong>in</strong>g late-stage pipel<strong>in</strong>e drugs, as well as<br />
heat maps and a competi<strong>to</strong>r matrix that compares safety and efficacy parameters<br />
- Additional <strong>in</strong>-depth analysis of the asthma cl<strong>in</strong>ical trials landscape, <strong>in</strong>clud<strong>in</strong>g trends <strong>in</strong> size, duration and<br />
failure rate<br />
- Forecast projections for the asthma market <strong>to</strong> <strong>2020</strong>, <strong>in</strong>clud<strong>in</strong>g analysis of the global market and each of<br />
the eight major markets and <strong>in</strong>corporat<strong>in</strong>g projected, low, and high-variance scenarios based on treatment<br />
usage patterns and annual cost of therapy <strong>in</strong> each of the major markets<br />
- Discussion of the strategic consolidations landscape, <strong>in</strong>clud<strong>in</strong>g trends <strong>in</strong> co-development and licens<strong>in</strong>g<br />
deals relevant <strong>to</strong> asthma drug products<br />
Access This Full Report @ http://www.radiant<strong>in</strong>sights.com/research/asthma-therapeutics-<strong>in</strong>major-developed-markets-<strong>to</strong>-<strong>2020</strong>-personalized-treatment-for-severe-asthma-<strong>to</strong>-drive-marketgrowth-despite-patent-expirations<br />
Reasons <strong>to</strong> buy<br />
The report will assist bus<strong>in</strong>ess development and enable market<strong>in</strong>g executives <strong>to</strong> strategize their product<br />
launches by allow<strong>in</strong>g them <strong>to</strong> -<br />
- Ga<strong>in</strong> a comprehensive understand<strong>in</strong>g of asthma, <strong>in</strong>clud<strong>in</strong>g diagnosis, disease severity, and treatment<br />
algorithms<br />
- Understand the current asthma marketed products landscape and recognize the dom<strong>in</strong>ant therapeutic<br />
agents and pharmaceutical players <strong>in</strong>volved<br />
- Identify trends, developments, and prom<strong>in</strong>ent molecule types and molecular targets with<strong>in</strong> the asthma<br />
pipel<strong>in</strong>e<br />
- Ga<strong>in</strong> an appreciation of the cl<strong>in</strong>ical and commercial aspects of the most promis<strong>in</strong>g late-stage pipel<strong>in</strong>e<br />
molecules and their potential competitive impact on the future market<br />
- Consider market opportunities and potential risks by exam<strong>in</strong><strong>in</strong>g trends <strong>in</strong> asthma cl<strong>in</strong>ical trial size,<br />
duration and failure rate, phase of development, molecule type, and molecular target<br />
- Observe projections for treatment usage patterns, annual therapy costs, and market growth <strong>in</strong> the eight<br />
major markets and understand reasons for variance <strong>in</strong> projected patterns of growth<br />
Table of Contents<br />
1 Table of Contents 5<br />
1.1 List of Tables 7
Change language